74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Eurazeo SE
Suletud
SektorRahandus
39.02 -2.6
Ülevaade
Aktsiahinna muutus
24h
Min
38.7
Max
39.42
Sissetulek | -309M |
|---|---|
Müük | 372M 283M |
Dividenditootlus | 6.36 |
Kasumimarginaal | 347.853 |
Töötajad | 438 |
EBITDA | -256M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +81.34% upside |
Dividenditootlus Sektori keskmine | 6.36% 4.84% |
|---|
Turukapital | -323M 2.6B |
|---|---|
Eelmine avamishind | 41.62 |
Eelmine sulgemishind | 39.02 |
Uudiste sentiment
By Acuity
41%
59%
136 / 441 Pingereas Finance
Tehniline skoor
By Trading Central
Kindlus
Strong Bullish Evidence
Eurazeo SE Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Eurazeo SE Prognoos
Hinnasiht
By TipRanks
81.34% tõus
12 kuu keskmine prognoos
Keskmine 72.5 EUR 81.34%
Kõrge 85 EUR
Madal 60 EUR
Põhineb 2 Wall Streeti analüütiku instrumendi Eurazeo SE 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
136 / 441 Pingereas Rahandus
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Eurazeo SE
Eurazeo SE is a private equity and venture capital firm specializing in growth capital, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in mid-market and listed public companies. The company invest in equity in the small-mid and Mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewellery, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc. The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in United States, France, Italy, North America and other European countries. It seeks to invest between "50 million ($54.35 million) to "250 million ($271.77 million) in small mid buyout business. It seeks to invest between "25 million ($27.18 million) to "100 million ($108.71 million) in growth business. It seeks to invest between "10 million ($10.82 million) and "40 million ($43.82 million) in the fields of healthcare research. It seeks to invests between equity investment between "1 million ($1.17 million) and "559.01 mil
Live chat